FDA Updates Mortality Rate Linked to Heart Pump in Post-Approval Study

Patients in a post-approval study (PAS) for Abiomed’s heart pump Impella RP reported lower survival rates when compared to premarket studies, the US Food and Drug Administration (FDA) reported Tuesday.